142 related articles for article (PubMed ID: 15715188)
1. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD.
Banerjee D; Khair OA; Honeybourne D
Respir Med; 2005 Feb; 99(2):208-15. PubMed ID: 15715188
[TBL] [Abstract][Full Text] [Related]
2. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial.
Banerjee D; Honeybourne D; Khair OA
Treat Respir Med; 2004; 3(1):59-65. PubMed ID: 15174894
[TBL] [Abstract][Full Text] [Related]
3. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Beeh KM; Beier J; Candler H; Wittig T
Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
[TBL] [Abstract][Full Text] [Related]
4. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
[TBL] [Abstract][Full Text] [Related]
5. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial.
Simpson JL; Powell H; Baines KJ; Milne D; Coxson HO; Hansbro PM; Gibson PG
PLoS One; 2014; 9(8):e105609. PubMed ID: 25148049
[TBL] [Abstract][Full Text] [Related]
6. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.
Uzun S; Djamin RS; Kluytmans J; Van't Veer NE; Ermens AA; Pelle AJ; Mulder P; van der Eerden MM; Aerts J
Trials; 2012 Jun; 13():82. PubMed ID: 22682323
[TBL] [Abstract][Full Text] [Related]
7. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD.
Powrie DJ; Wilkinson TM; Donaldson GC; Jones P; Scrine K; Viel K; Kesten S; Wedzicha JA
Eur Respir J; 2007 Sep; 30(3):472-8. PubMed ID: 17504798
[TBL] [Abstract][Full Text] [Related]
8. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
[TBL] [Abstract][Full Text] [Related]
9. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.
Patel IS; Seemungal TA; Wilks M; Lloyd-Owen SJ; Donaldson GC; Wedzicha JA
Thorax; 2002 Sep; 57(9):759-64. PubMed ID: 12200518
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.
Wilson R; Anzueto A; Miravitlles M; Arvis P; Haverstock D; Trajanovic M; Sethi S
Int J Chron Obstruct Pulmon Dis; 2015; 10():985-93. PubMed ID: 26082623
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Herath SC; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD009764. PubMed ID: 24288145
[TBL] [Abstract][Full Text] [Related]
12. Multi-site placebo-controlled randomised clinical trial to assess protection following oral immunisation with inactivated non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease.
Clancy RL; Dunkley ML; Sockler J; McDonald CF
Intern Med J; 2016 Jun; 46(6):684-93. PubMed ID: 27009822
[TBL] [Abstract][Full Text] [Related]
13. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
14. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease.
Soler N; Agustí C; Angrill J; Puig De la Bellacasa J; Torres A
Thorax; 2007 Jan; 62(1):29-35. PubMed ID: 16928715
[TBL] [Abstract][Full Text] [Related]
15. Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation.
Tufvesson E; Bjermer L; Ekberg M
Int J Chron Obstruct Pulmon Dis; 2015; 10():881-9. PubMed ID: 26005341
[TBL] [Abstract][Full Text] [Related]
16. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD.
Matthys H; Pliskevich DA; Bondarchuk OM; Malek FA; Tribanek M; Kieser M
Respir Med; 2013 May; 107(5):691-701. PubMed ID: 23478193
[TBL] [Abstract][Full Text] [Related]
17. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
18. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS).
Celli B; Halpin D; Hepburn R; Byrne N; Keating ET; Goldman M
Respir Med; 2003 Jan; 97 Suppl A():S35-43. PubMed ID: 12564609
[TBL] [Abstract][Full Text] [Related]
19. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial.
Robinson P; Schechter MS; Sly PD; Winfield K; Smith J; Brennan S; Shinkai M; Henke MO; Rubin BK
Pediatr Pulmonol; 2012 Jun; 47(6):551-7. PubMed ID: 22266895
[TBL] [Abstract][Full Text] [Related]
20. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
